NEURELIS ANNOUNCES COMPLETION OF SENIOR MANAGEMENT TEAM BUILDOUT TO SUPPORT THE ANTICIPATED COMMERCIAL LAUNCH OF VALTOCO™
— Neurelis’ lead product candidate for seizures, VALTOCO™ (diazepam nasal spray), currently under FDA review — Company’s team members are all seasoned pharmaceutical industry executives with vast experience in CNS and epilepsy SAN DIEGO, CA – April 22, 2019 – Neurelis, Inc., a privately held specialty pharmaceutical company focused on licensing, developing, and commercializing product candidates […]